With generic pharmaceuticals all the rage these days, it's only fitting that Eon Labs
Eon now expects fourth-quarter sales between $85 million and $90 million, up significantly from its previous $75 million to $80 million forecast. The company also expects fourth-quarter earnings at $0.05 higher than its previously expected, coming in at $0.38 to $0.41 per share. Similarly, full-year sales will be between $320 million and $325 million, with earnings of $1.51 to $1.54 per share.
Over the past year or so, we've given generic drug makers a lot of thought. For starters, check out Jeff Fischer's three-part series from last spring: Generic Drugs' High Potential, a discussion on Mylan Labs
Among the issues we've covered of late, IVAX
As for Eon itself, it has earned a reasonably rich price tag at about 29 times 2004 earnings. In current trends keep apace, future profits for the drug maker may be looking much more "high-end."